Literature DB >> 2296090

A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.

P A Broliden1, K Ljunggren, J Hinkula, E Norrby, L Akerblom, B Wahren.   

Abstract

Monoclonal antibodies (MAbs) were raised against human immunodeficiency virus type 1 gp120. One MAb, P4/D10, was found to mediate highly efficient antibody-dependent cellular cytotoxicity and virus neutralization. The reactivity was located to a major neutralizing region (amino acids 304 to 323) on gp120. Five other MAbs with a similar epitopic reactivity did not show any antibody-dependent cellulan cytotoxicity activity but had a virus-neutralizing capacity.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2296090      PMCID： PMC249194     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  28 in total

1.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.

Authors:  L A Lasky; J E Groopman; C W Fennie; P M Benz; D J Capon; D J Dowbenko; G R Nakamura; W M Nunes; M E Renz; P W Berman
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

4.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

5.  Observations of IgG1 anti-DNP hybridoma-mediated ADCC and the failure of three IgM anti-DNP hybridomas to mediate ADCC.

Authors:  A H Greenberg; P M Lydyard
Journal:  J Immunol       Date:  1979-08       Impact factor: 5.422

6.  Cell-mediated lysis of tumor targets directed by murine monoclonal antibodies of IgM and all IgG isotypes.

Authors:  P Ralph; I Nakoinz
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

7.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex.

Authors:  M Robert-Guroff; M Brown; R C Gallo
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

8.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients.

Authors:  R A Weiss; P R Clapham; R Cheingsong-Popov; A G Dalgleish; C A Carne; I V Weller; R S Tedder
Journal:  Nature       Date:  1985 Jul 4-10       Impact factor: 49.962

9.  IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.

Authors:  D Herlyn; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

10.  Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies.

Authors:  T J Kipps; P Parham; J Punt; L A Herzenberg
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307
View more
  20 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

3.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 4.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

5.  Comparison of human immunodeficiency virus (HIV)-specific infection-enhancing and -inhibiting antibodies in AIDS patients.

Authors:  Ramu A Subbramanian; Jingwu Xu; Emil Toma; Richard Morisset; Eric A Cohen; José Menezes; Ali Ahmad
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity.

Authors:  E Björling; K Broliden; D Bernardi; G Utter; R Thorstensson; F Chiodi; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

7.  Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates.

Authors:  K Schlienger; M Mancini; Y Rivière; D Dormont; P Tiollais; M L Michel
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.

Authors:  C F Barbas; E Björling; F Chiodi; N Dunlop; D Cababa; T M Jones; S L Zebedee; M A Persson; P L Nara; E Norrby
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

9.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

10.  Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1.

Authors:  J F Dedieu; J Ronco; S van der Werf; J M Hogle; Y Henin; M Girard
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.